Results 21 to 30 of about 1,643 (175)

A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol [PDF]

J Pers Med
Meloche M, Pilon M, Provost S, Leclair G, Oussaïd E, St-Jean I, Jutras M, Gaulin M, Lemieux Perreault L, Valois D, Mongrain I, Busseuil D, Rouleau J, Tardif J, Dubé M, de Denus S.   +15 more
europepmc   +5 more sources

A Pharmacometric Workflow for Resolving Model Instability in Model Use-Reuse Settings. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT The development of fit‐for‐purpose pharmacokinetic‐pharmacodynamic (PKPD) models based on clinical and pre‐clinical data is a critically important process in model informed drug development. This process is often hampered by modeling stability issues that are often multifactorial in nature and difficult to overcome, leading to protracted model
Duffull SB, Wright DFB, Zhu X, Liu X, Abulfathi A, Hishe H.   +5 more
europepmc   +2 more sources

Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects [PDF]

British Journal of Clinical Pharmacology, 1996
1 Eight healthy subjects received 50, 100, 300, 600 and 900 mg allopurinol daily for 1 week each, in random order with 1 week separating each treatment period. The pre‐dose plasma concentration of oxypurinol, the extent of inhibition of xanthine oxidase, plasma urate concentration and urine urate excretion rate were assessed on the last 2 days of each
Steven H. Graham, Richard O. Day, Hong Yuen Wong, Andrew J. McLachlan, L Bergendal, John O. Miners, Donald Birkett   +6 more
openalex   +4 more sources

Reduced Serum Urate Concentrations Despite Unchanged Allopurinol Dosing in Gout Patients Commenced on Dialysis: A Retrospective Chart Review [PDF]

Nephrology (Carlton)
The study investigated allopurinol dosing practises and serum urate concentrations in gout patients with kidney failure following commencing dialysis. Results showed allopurinol dose was most commonly 100 mg, unadjusted upon commencing dialysis. However, serum urate concentrations significantly declined as patients commenced dialysis with more than 50%
Kamel N, Castelino R, Wright D, Sud K, Tarafdar S, Hughes S, Stocker S.   +6 more
europepmc   +2 more sources

Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. [PDF]

Annals of the Rheumatic Diseases, 1991
The effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol were investigated. Pyrazinamide decreased the mean (SEM) fractional clearance of oxypurinol from 19.2 (2.1) to 8.8 (1.5). Probenecid increased the fractional clearance of oxypurinol from 14.1 (3.5) to 24.8 (4.1).
Tetsuya Yamamoto, Yasuhiro Moriwaki, Satoru Takahashi, Mitsuaki Suda, Kazuya Higashino   +4 more
openalex   +4 more sources

1‐Methylxanthine derived from caffeine as a pharmacodynamic probe of oxypurinol effect [PDF]

British Journal of Clinical Pharmacology, 1997
Aims In the present study we have investigated the use of caffeine, administered in the form of instant coffee, as a prodrug for 1MX to validate the use of the 1MU:1MX ratio following caffeine administration as a pharmacodynamic measure of oxypurinol effect on xanthine oxidase.
D. J. Birkett, John O. Miners, Luísa M.P. Valente, K.J. Lillywhite, Richard O. Day   +4 more
openalex   +4 more sources

An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites

Clinical and Translational Science, 2022
ABCG2 is a gene that codes for the human breast cancer resistance protein (BCRP). It is established that rs2231142 G>T, a single nucleotide polymorphism of the ABCG2 gene, is associated with gout and poor response to allopurinol, a uric acid‐lowering ...
Marc‐Olivier Pilon, Grégoire Leclair, Essaïd Oussaïd, Isabelle St‐Jean, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean Lucien Rouleau, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus   +11 more
doaj   +1 more source

Binding of Xanthine Oxidase to Glycosaminoglycans Limits Inhibition by Oxypurinol [PDF]

Journal of Biological Chemistry, 2004
Although the binding of xanthine oxidase (XO) to glycosaminoglycans (GAGs) results in significant alterations in its catalytic properties, the consequence of XO/GAG immobilization on interactions with clinically relevant inhibitors is unknown. Thus, the inhibition kinetics of oxypurinol for XO was determined using saturating concentrations of xanthine.
Eric E. Kelley, Andrés Trostchansky, Homero Rubbo, Bruce Α. Freeman, Rafael Radí, Margaret M. Tarpey   +5 more
openalex   +4 more sources

Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Allopurinol is used to treat hyperuricemia and gout. It is metabolized to oxypurinol by xanthine oxidase (XO), and aldehyde oxidase (AO). Allopurinol and oxypurinol are potent XO inhibitors that reduce the plasma uric acid levels.
Yoshitaka Tayama, Kazumi Sugihara, Seigo Sanoh, Katsushi Miyake, Shigeyuki Kitamura, Shigeru Ohta   +5 more
doaj   +1 more source

The impact of peritoneal dialysis on oxypurinol and urate elimination in people with gout [PDF]

Nephrology, Volume 29, Issue 8, Page 547-550, August 2024.
Abstract Gout affects 15%–30% of individuals with advanced kidney disease. Allopurinol which is rapidly and extensively metabolised to an active metabolite, oxypurinol, is the most commonly prescribed urate‐lowering therapy. Oxypurinol is almost entirely eliminated by the kidneys (>95%) and has an elimination half‐life of 18–30 h in those with normal ...
Luke C. Wilson, Jacob Ward, Daniel F. B. Wright, Suetonia C. Green, Sophie L. Stocker, Tracey Putt, John Schollum, Robert Walker   +7 more
openalex   +2 more sources